A New Way to
Detect Cancer

DELFI at AACR 2023

As a next-generation liquid biopsy company, DELFI Diagnostics is developing a rich pipeline of products designed to save lives by detecting cancer at its earliest stages. Our whole-genome fragmentomics platform is capable of supporting a broad range of high-performing applications to address major unmet medical needs in cancer.

Come see our presentations at AACR or stop by Booth 3355 to learn more about DELFI and our rigorous, sustainable approach to delivering new, better solutions to patients, providers, and health systems.




Prospective evaluation of cell-free DNA fragmentomes for lung cancer detection

Session Title: Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities

Session Date/Time: 4/18/23, 2:52 PM – 3:07 PM ET

Room: W304 E-H – Convention Center

Download Slides


Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer

Session Title: Increasing the Clinical Utility of Cell-Free DNA Testing

Session Date/Time: 4/18/23, 3:52 PM – 4:07 PM ET

Room:  Valencia D – Convention Center

Download Slides



Early detection of ovarian cancer using cell-free DNA fragmentomes

Session Title: Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment

Session Date and Time:4/16/23, 1:30 PM – 5:00 PM ET

Location: Section 28

Poster Board Number: 15

Learn More


CASCADE-LUNG: Validation of a blood-based assay that evaluates cell-free DNA fragmentation patterns to detect lung cancer

Session Title: Phase II and Phase III Clinical Trials in Progress

Session Date and Time: 4/17/23, 9:00 AM – 12:30 PM ET

Location: Section 46

Poster Board Number: 26

Download Poster